Alebund

Alebund is a clinical biopharmaceutical company primarily dedicated to the discovery and development of products for kidney diseases and their complications, as well as other chronic conditions. Established in 2018 and backed by leading global venture capital, Alebund possesses robust internal discovery and clinical development capabilities, along with licensing expertise. Alebund focuses on discovering and developing novel therapies mainly for the treatment of kidney diseases and their complications, as well as other chronic conditions. Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of kidney diseases, including complications of chronic kidney disease (CKD)/dialysis, IgA nephropathy, diabetic nephropathy, and autosomal dominant polycystic kidney disease (ADPKD). Alebund’s pipeline includes both small molecules and biological assets.